Jupiter Topco LLC Purchases Shares of 8,075,934 Abbott Laboratories $ABT

Key Points

• Jupiter Topco LLC acquired 8.08 million Abbott shares in the second quarter, valued at approximately $732.8 million and representing about 0.47% of the company. Institutional investors and hedge funds collectively own 75.18% of Abbott.
• Abbott exceeded quarterly expectations with EPS of $1.31 versus the $1.28 consensus and revenue of $12.59 billion, up 13% year over year. The company maintained 2026 guidance and pays a quarterly dividend of $0.63, yielding about 2.3% annually.
• Analyst sentiment remains positive: Abbott has a “Moderate Buy” consensus rating and an average price target of $119.50, while recent target increases include TD Cowen’s $135 objective. The company is also expanding its nutrition portfolio with a ready-to-feed whole-milk infant formula.

Jupiter Topco LLC acquired a new position in shares of Abbott Laboratories (NYSE:ABT - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 8,075,934 shares of the healthcare product maker's stock, valued at approximately $732,788,000. Jupiter Topco LLC owned approximately 0.47% of Abbott Laboratories as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in ABT. Brighton Jones LLC raised its stake in shares of Abbott Laboratories by 10.1% in the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker's stock valued at $5,850,000 after purchasing an additional 4,755 shares during the period. Sivia Capital Partners LLC boosted its position in shares of Abbott Laboratories by 3.5% during the second quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker's stock worth $648,000 after buying an additional 162 shares during the period. United Bank grew its holdings in shares of Abbott Laboratories by 7.4% during the second quarter. United Bank now owns 29,004 shares of the healthcare product maker's stock worth $3,945,000 after buying an additional 2,001 shares in the last quarter. Main Street Financial Solutions LLC grew its holdings in shares of Abbott Laboratories by 13.6% during the second quarter. Main Street Financial Solutions LLC now owns 11,894 shares of the healthcare product maker's stock worth $1,618,000 after buying an additional 1,428 shares in the last quarter. Finally, Canada Pension Plan Investment Board raised its position in Abbott Laboratories by 25.6% in the 2nd quarter. Canada Pension Plan Investment Board now owns 1,435,683 shares of the healthcare product maker's stock valued at $195,267,000 after buying an additional 292,547 shares during the last quarter. 75.18% of the stock is owned by institutional investors and hedge funds.

Abbott Laboratories Price Performance

NYSE:ABT opened at $108.86 on Wednesday. The stock has a market capitalization of $188.37 billion, a PE ratio of 35.23, a P/E/G ratio of 2.05 and a beta of 0.59. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $137.49. The firm has a fifty day simple moving average of $103.43 and a 200 day simple moving average of $100.09. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.03. The firm had revenue of $12.59 billion for the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The company's quarterly revenue was up 13.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, research analysts expect that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, August 17th. Investors of record on Wednesday, July 15th were paid a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 2.3%. The ex-dividend date was Wednesday, July 15th. Abbott Laboratories's dividend payout ratio (DPR) is 81.55%.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: New infant formula expands Abbott’s nutrition portfolio. Abbott launched Similac 360 Total Care Made With Whole Milk, described as the first commercially sterile, ready-to-feed liquid whole-milk infant formula available in the U.S. The product targets growing parental interest in whole-milk formulas while offering convenience at a price similar to Similac’s powdered formula. Wider distribution and consumer adoption could provide incremental growth for Abbott’s Nutrition segment. Abbott launches whole-milk liquid infant formula
• Positive Sentiment: Analysts remain optimistic despite relative underperformance. Coverage notes that ABT has lagged the broader healthcare sector over the past year, but Wall Street analysts continue to express confidence in the company’s outlook. Recent earnings also showed revenue growth, an earnings-per-share beat and reaffirmed 2026 guidance, supporting the bullish view. Abbott stock and healthcare-sector performance
• Neutral Sentiment: Abbott is positioning the launch around changing consumer and policy preferences. The whole-milk formula introduction aligns with interest in “Make America Healthy Again” themes, but the financial impact will depend on demand, pricing and market share gains. Abbott and the Make America Healthy Again movement
• Negative Sentiment: Formula-related advertising scrutiny remains a risk. In a challenge brought by Abbott, the National Advertising Division supported certain Kendamil whole-milk claims but recommended that other nutritional, ingredient and heritage claims be modified or discontinued. The decision is not a direct finding against Abbott, but it highlights competitive scrutiny in the infant-formula market. NAD decision on Kendamil infant formula claims

Analyst Ratings Changes

Several equities analysts have recently weighed in on ABT shares. TD Cowen raised their price target on shares of Abbott Laboratories from $115.00 to $135.00 and gave the stock a "buy" rating in a research note on Tuesday, August 25th. JPMorgan Chase & Co. increased their target price on shares of Abbott Laboratories from $110.00 to $120.00 and gave the stock an "overweight" rating in a report on Friday, July 17th. Citigroup raised their target price on shares of Abbott Laboratories from $108.00 to $112.00 and gave the company a "buy" rating in a research report on Friday, July 17th. Weiss Ratings upgraded shares of Abbott Laboratories from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Thursday, August 6th. Finally, The Goldman Sachs Group reduced their price objective on shares of Abbott Laboratories from $121.00 to $113.00 and set a "buy" rating for the company in a research note on Wednesday, May 27th. Three investment analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $119.50.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source